Pardes Biosciences to Present at the International Conference On Antiviral Research 2022

Rhea-AI Summary

Pardes Biosciences (NASDAQ: PRDS) announced its oral presentation at the 35th International Conference on Antiviral Research (ICAR) 2022, focusing on their antiviral drug candidate PBI-0451 for COVID-19. The presentation, titled "Profile of PBI-0451 an Orally Administered 3CL Protease Inhibitor of SARS-CoV-2 for COVID-19," is scheduled for March 24, 2022, during the Coronaviruses session from 2:45-5:45 p.m. PT. Attendees can access the session on the ICAR virtual platform until April 25, 2022.

CARLSBAD, Calif. , March 21, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential unboosted novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that it will give an oral presentation at the 35^th International Conference On Antiviral Research (ICAR) 2022, to be held in Seattle and virtually from March 21-25 2022.

Details of Pardes’ oral presentation:

Title: Profile of PBI-0451 an Orally Administered 3CL Protease Inhibitor of SARS-CoV-2 for COVID-19
Presentation Date: Thursday, March 24, 2022
Session: Coronaviruses (2:45-5:45 p.m. PT)

Registered attendees will be able to view the presentation session on the ICAR virtual platform, which will be available live or on-demand through April 25, 2022.

About Pardes Biosciences, Inc. 

Pardes Biosciences is a clinical-stage biopharmaceutical company created to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates. For more information, please visit www.pardesbio.com.

Availability of Other Information about Pardes Biosciences

Pardes Biosciences intends to use the Investors page of its website (https://ir.pardesbio.com) as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD (Fair Disclosure). Accordingly, investors should monitor Pardes Biosciences’ Investors website, in addition to following Pardes’ press releases, Securities and Exchange Commission filings, public conference calls, presentations and webcasts.

Investor Contact:
ir@pardesbio.com

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

FAQ

What is the focus of Pardes Biosciences' presentation at ICAR 2022?

Pardes Biosciences is presenting on PBI-0451, a potential oral antiviral drug for COVID-19.

When will Pardes Biosciences present at the ICAR 2022 conference?

Pardes Biosciences' presentation is scheduled for March 24, 2022.

What is PBI-0451 developed by Pardes Biosciences?

PBI-0451 is a novel direct-acting, oral antiviral drug candidate targeting SARS-CoV-2.

Where can attendees view Pardes Biosciences' ICAR presentation?

The presentation can be viewed live or on-demand on the ICAR virtual platform until April 25, 2022.

What is the significance of the presentation by Pardes Biosciences at ICAR?

The presentation highlights advancements in developing antiviral treatments for COVID-19.